This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Enzo Biochem’s Clinical Lab Acquires Marketing Rights To Unique, More Effective Diagnostic Test For Cervical Cancer

Enzo Biochem Inc. (NYSE:ENZ), as part of its continuing program to offer novel molecular tests, announced that its Enzo Clinical Labs subsidiary has reached an agreement with IncellDx Inc. of Menlo Park, CA, for the rights to market a proprietary laboratory test. The test is based upon HPV OncoTect™, an advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer and will further expand Enzo’s approach to providing comprehensive clinical information to physicians for managing diseases associated with women’s health. Upon receiving the appropriate approvals, Enzo will become the first New York licensed reference laboratory to offer the test.

HPV OncoTect™ is a novel method for screening for the likelihood of progression to cervical carcinoma by measuring potential oncogenic activity of the human papillomavirus (HPV) in infected cervical cells. The assay functions by detecting and quantifying the expression of viral oncogenes responsible for triggering progression to cervical cancer, thus improving the specificity that existing tests lack. As with other assays developed at Enzo Clinical Labs, HPV OncoTect™ will be validated during in-house studies prior to seeking New York State approval under a “LDT” regulatory pathway. Favorable reimbursement already exists for this type of testing.

“The HPV OncoTect™ technology is a flow-cytometry based method that can be used to identify the genetic expression of HPV that has already integrated into the cell, offering a better indicator of serious HPV infections than can be accomplished by identifying the presence of the virus alone,” said Dr. Robert Boorstein, MD, PhD., Medical Director of Enzo Clinical Labs. "This addition to our growing line of molecular diagnostic tests for women’s health underscores our expanding specialization in advanced clinical and diagnostic testing. We intend to use this test initially for patients who have been shown to be HPV positive by standard techniques”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs